Skip to content

Comparison Between Myopia Versus Hypermetropia With Progressive Addition Lenses in Computer Users

Comparison Between Myopia Versus Hypermetropia With Progressive Addition Lenses in Computer Users

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06484257
Enrollment
64
Registered
2024-07-03
Start date
2023-11-01
Completion date
2024-10-30
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypermetropia, Myopia

Brief summary

This study examines how myopia (nearsightedness) and hyperopia (farsightedness) affect the use of progressive addition lenses (PALs) for computer users. PALs offer a range of vision correction within one lens, ideal for presbyopia (age-related near focusing difficulty). We'll compare visual comfort, eye strain, and user preference for PALs between myopic and hyperopic individuals while focusing on computer screens.

Detailed description

The research will also consider if general-purpose PALs differ from computer-specific PALs in these user groups, and how presbyopia progression might influence PAL effectiveness for each condition. This information can help eye doctors recommend the most suitable PAL design for computer users with myopia or hyperopia.

Interventions

BEHAVIORALMyopia

Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.

OTHERHypermetropia

Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.

Sponsors

Superior University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* The age of Participant will be 40 to 55 years * Participant diagnosed with myopia having -0.50 to -3.00DS and astigmatism up to -0.75DC * Patient diagnosed with Hypermetropia having +050 to +3.00 DS and Astigmatism up to +0.75DC * Presbyopia addition will range from +1.00 to +2.50 DS * Participants who have worked more than 4 hours on the computer screen. * Participants who will be already progressive users and first-time users. * Patients with no Ocular disease.

Exclusion criteria

* Participants with Pre Presbyopia and above 55 years of age * Participants with significant ocular disease. * Participants with uncontrolled diabetes and hypertension * Participants who will not be willing for PAL,s * Participants with more than 0.75 astigmatism * Participants with known allergies and sensitivity.

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity12 MonthsAssessing visual acuity at different distances, including distance vision (for activities such as viewing the computer screen) and near vision (for reading text on the screen), while wearing progressive addition lenses.
Subjective Visual Comfort12 monthsUsing standardized questionnaires or subjective ratings from participants to assess their comfort level while using computers with progressive addition lenses.
Visual Fatigue12 monthsAssessing the level of visual fatigue experienced by participants during or after prolonged computer use with the progressive addition lenses. This could involve subjective ratings of eye strain, tiredness, or discomfort.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026